Loading
LUMINA used tumour biology, not just age, to pick women who can skip breast radiotherapy: with a luminal A profile and endocrine therapy, local recurrence at five years was about two percent.
LUMINA was a single-arm prospective study of 500 women aged 55 or older with grade 1 or 2 T1N0 luminal A breast cancer (oestrogen and progesterone receptor-positive, HER2-negative, Ki67 of 13.25 percent or less) who had breast-conserving surgery and endocrine therapy and no radiotherapy. Five-year local recurrence was 2.3 percent, 90 percent confidence interval 1.3 to 3.8 (Whelan and colleagues, New England Journal of Medicine 2023;389:612 to 619), supporting biomarker-based omission.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
500 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Local recurrence at 5 yearsprimary | Endocrine therapy, no radiotherapy | 500 | 2.3% | - | - | - |
This is the paper Europe PMC returns for registry id NCT01791829 with the most citations, so it is the natural first reading for anyone following the LUMINA trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag radiation-wave2.
Shares Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag radiation-wave2.
Shares Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag radiation-wave2.
Shares Breast cancer (all types), HR-positive / HER2-negative breast cancer and the tag radiation-wave2.
Shares Leaving radiotherapy out, Breast cancer (all types), HR-positive / HER2-negative breast cancer.
Shares Leaving radiotherapy out, Breast cancer (all types), HR-positive / HER2-negative breast cancer.
Shares Active surveillance, Breast cancer (all types), HR-positive / HER2-negative breast cancer.
Shares Leaving radiotherapy out, Breast cancer (all types), HR-positive / HER2-negative breast cancer.